NasdaqGM:SMMTBiotechs
How Summit’s Deeper 2025 Loss and Ivonescimab’s FDA Path At Summit Therapeutics (SMMT) Has Changed Its Investment Story
Summit Therapeutics Inc. has reported full-year 2025 results, with net loss widening to US$1,079.59 million and basic and diluted loss per share from continuing operations rising to US$1.44, while also filing a US$102.02 million shelf registration for 6,400,000 common shares under an ESOP-related offering.
Alongside these figures, management emphasized a platform-based approach for ivonescimab, underscoring its four positive Phase III readouts and a clearly defined U.S. FDA review...